Review: Advanced non-small cell lung cancer: the role of maintenance therapy-Reference-Cited by-同舟云学术

Review: Advanced non-small cell lung cancer: the role of maintenance therapy

Published:2009-12-08 Issue:1 Volume:2 Page:17-23
ISSN:1758-8359
Container-title:Therapeutic Advances in Medical Oncology
language:en
Short-container-title:Ther Adv Med Oncol

Author:

Agarwala Anuj K.¹,Hanna Nasser H.²

Affiliation:

1. Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN 46202-5289, USA

2. Indiana University Melvin and Bren Simon Cancer Center, 535 Barnhill Drive, RT 473, Indianapolis, IN 46202-5289, USA

Abstract

Platinum-based chemotherapy has been shown to provide survival benefits in advanced non-small cell lung cancer (NSCLC). Maintenance/consolidation chemotherapy in NSCLC has gained renewed interest with improved tolerability of chemotherapy and the addition of biologic agents. Various studies have evaluated the role of prolonged duration of chemotherapy as well as maintenance/consolidation strategies with both chemotherapy and biologic agents. The available data at this time demonstrates that maintenance or consolidation therapy can improve progression free survival; however this does not result consistently in an improved overall survival. We review the literature with regard to duration of therapy and use of maintenance/consolidation therapy in advanced NSCLC.

Publisher

SAGE Publications

Subject

Oncology

Link

http://journals.sagepub.com/doi/pdf/10.1177/1758834009351443

Reference28 articles.

1. Maintenance pemetrexed (Pem) plus best supportive care (BSC) versus placebo (Plac) plus BSC: A randomized phase III study in advanced non-small cell lung cancer (NSCLC)

2. Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: A phase III trial

3. SATURN: A double-blind, randomized, phase III study of maintenance erlotinib versus placebo following nonprogression with first-line platinum-based chemotherapy in patients with advanced NSCLC

4. Phase III Study of Immediate Compared With Delayed Docetaxel After Front-Line Therapy With Gemcitabine Plus Carboplatin in Advanced Non–Small-Cell Lung Cancer

5. Phase III Study of Erlotinib in Combination With Cisplatin and Gemcitabine in Advanced Non–Small-Cell Lung Cancer: The Tarceva Lung Cancer Investigation Trial

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immune Checkpoint Inhibitors as Switch or Continuation Maintenance Therapy in Solid Tumors: Rationale and Current State;Targeted Oncology;2019-09-18